Cytek Biosciences, Inc. · NASDAQ:CTKB
Cytek Biosciences — Q2 2026 Earnings Presentation
15 slides from Cytek Biosciences's earnings presentation, Aug 5, 2026
Slide 1: Q2 2026 Earnings Presentation
Q2 2026 Earnings Presentation August 5, 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and the related conference call and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek’s future financial performance, including its outlook
Slide 3: Q2 2026 Revenue Results
Q2 2026 Revenue Results1 Service Revenue Product Revenue $62.1 +8% Y/Y Q2 2026 Commentary $52.3 +2% Y/Y $48.1 $45.6 $15.5 $44.1 +6% Y/Y Continued positive momentum through the -2% Y/Y +6% Y/Y second quarter, delivering another period of $14.2 solid revenue growth $15.6 $14.2 $15.4 $46.6 Q2 2026 Reve
Slide 4: Revenue by Geographic Region
Revenue by Geographic Region1 Other APAC EMEA Q2 2026 Commentary United States $62.1 +8% Y/Y US: Revenue was up 18% Y/Y driven by $52.3 $3.7 impressive growth in instruments in academic $45.6 +2% Y/Y $48.1 and government and services $13.2 $44.1 +6% Y/Y -2% Y/Y +6% Y/Y $11.1 $7.9 EMEA: Revenue was d
Slide 5: Q2 Business Highlights
Q2 Business Highlights1 Expanded to a total installed Solid instrument unit growth in Q2 Grew Cytek Cloud to over 28K base of 3,933 Cytek instruments, driven by high-end instruments, users in Q2 2026, up 15% since adding 142 units in Q2 which increased by 11% Y/Y the start of the year Launched Cytek
Slide 6: Cytek Borealis Flow Cytometer
Extending our Leadership in the Spectral Flow Cytometry Market INTRODUCING THE NEW Cytek Borealis Flow Cytometer Revolutionary, next-generation flow cytometry First-ever 60 color, 7-laser Flow Cytometer with proprietary matching reagents Accommodates nanoparticle sizes enabling a high diversity of s
Slide 7: Cytek Aurora Evo
Strengthening our Market Leadership INTRODUCING THE NEW Cytek Aurora Evo with enhanced automation capabilities Full-spectrum 40+ color, 5-laser Flow Cytometry Expanded automation capabilities for highly-automated laboratory environments Automated and remote start-up, shut-down, door operation, monit
Slide 8: Revenue Mix
Revenue Mix By Region Product & Service +6% Y/Y +6% Y/Y $48.1 $48.1 $45.6 $45.6 $7.9 $7.9 $15.6 $14.2 $11.3 $12.3 $31.4 $32.6 $28.2 Other $23.9 APAC Service Revenue EMEA Product United States Revenue Q2 2025 Q2 2026 Q2 2025 Q2 2026 18% Y/Y US Growth 10% Y/Y Service Growth In $ Millions 8
Slide 9: Q2 2026 Financial Overview
Q2 2026 Financial Overview $ in millions Q2 2025 Q2 2026 Y/Y Total Revenue $45.6 $48.1 6% Gross Profit $23.9 $28.3 19% Gross Margin 52% 59% NM Operating Expenses: Research and Development $8.8 $9.7 10% Sales and Marketing $12.1 $13.2 9% General and Administrative1 $13.5 $16.8 24% Total Operating Exp
Slide 10: Updated 2026 revenue guidance, increasing by $1M at the midpoint
FY 2026 Revenue Guidance1 Updated 2026 revenue $207 - $212 guidance, increasing by million $1M at the midpoint +3 to +5% Y/Y growth 1. Assumes no change from current currency exchange rates 10
Slide 11: 2026 Strategic Priorities
2026 Strategic Priorities Attractive Financial Profile Growing Recurring Revenue Well-positioned to Technology Platform deliver long-term Leader Drive reagent and profitable, Global Diversification service businesses sustainable growth Advance technological benefitting from through differentiated le
Slide 12: Appendix
Appendix 12
Slide 13: Creating New Business Units to Drive Growth
Creating New Business Units to Drive Growth Aligns sales, marketing and R&D resources on distinct customer needs to accelerate Cytek’s growth 1 2 3 Research Technology Solutions and Clinical Service Business Unit Business Unit Business Unit High-end instruments to Low/mid-range instruments and Syste
Slide 14: Reconciliation of GAAP to Non-GAAP Measures (Unaudited)
Reconciliation of GAAP to Non-GAAP Measures (Unaudited) Three Months Ended Six Months Ended (In thousands) June 30, 2026 June 30, 2025 June 30, 2026 June 30, 2025 GAAP gross profit $ 28,340 $ 23,867 $ 49,594 $ 44,024 Stock based compensation $ 736 $ 1,110 $ 1,465 $ 2,196 Amortization of acquisition-
Slide 15: Thank You
CYTE Ko “TRANSCEND THE CONVENTIONAL